drugset / Trial / NCT01439126
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Timeline
- Start
- 2011-08
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clonidine | Other / unclassified | 0.1 mg | — |
| Comparator | Clonidine | Other / unclassified | 0.2 mg | — |
| Comparator | Clonidine | Other / unclassified | 0.3 mg | — |
| Comparator | Clonidine | Other / unclassified | 0.4 mg | — |